Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication
PURPOSE: We tested the hypothesis that propionyl-L-carnitine would improve peak walking time in patients with claudication. Secondary aims of the study were to evaluate the effects of propionyl-L-carnitine on claudication onset time, functional status, and safety. SUBJECTS AND METHODS: In this doubl...
Gespeichert in:
| Veröffentlicht in: | The American journal of medicine 2001-06, Vol.110 (8), p.616-622 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 622 |
|---|---|
| container_issue | 8 |
| container_start_page | 616 |
| container_title | The American journal of medicine |
| container_volume | 110 |
| creator | Hiatt, William R Regensteiner, Judith G Creager, Mark A Hirsch, Alan T Cooke, John P Olin, Jeffrey W Gorbunov, Georgij N Isner, Jeffrey Lukjanov, Yurij V Tsitsiashvili, Mihail Sh Zabelskaya, Tatyana F Amato, Antonino |
| description | PURPOSE: We tested the hypothesis that propionyl-L-carnitine would improve peak walking time in patients with claudication. Secondary aims of the study were to evaluate the effects of propionyl-L-carnitine on claudication onset time, functional status, and safety.
SUBJECTS AND METHODS: In this double-blind, randomized, placebo-controlled trial, 155 patients with disabling claudication from the United States (n = 72) or Russia (n = 83) received either placebo or propionyl-L-carnitine (2g/day orally) for 6 months. Subjects were evaluated at baseline and 3 and 6 months after randomization with a graded treadmill protocol at a constant speed of 2 miles per hour, beginning at 0% grade, with increments in the grade of 2% every 2 minutes until maximal symptoms of claudication forced cessation of exercise. Questionnaires were used to determine changes in functional status.
RESULTS: At baseline, peak walking time was 331 ± 171 seconds in the placebo group and 331 ± 187 seconds in the propionyl-L-carnitine group. After 6 months of treatment, subjects randomly assigned to propionyl-L-carnitine increased their peak walking time by 162 ± 222 seconds (a 54% increase) as compared with an improvement of 75 ± 191 seconds (a 25% increase) for those on placebo (
P |
| doi_str_mv | 10.1016/S0002-9343(01)00704-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70866425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002934301007045</els_id><sourcerecordid>70866425</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-6da197fda28fa418377c1318de8a551d02bed398452b151b7c410dbeceaeae5e3</originalsourceid><addsrcrecordid>eNpd0VtrFTEQB_Agij1WP4ISBMU-rGZy2cuTlOINCgrqc5hNZjVlbybZXr69Oe1RQfIQAr8kM_Nn7CmI1yCgfvNVCCGrTmn1SsCJEI3QlbnHdmCMqRqo5X22-0uO2KOULspRdKZ-yI4AVCtV3e3Yjy9xWcMy34zVeeUwziGHmXiY1rhcUuJ0TdGFRHylOCxxwtkRx9nzYZtdLhdx5Clj3hIPM18xB5pz4lch_-RuxM0Hh3v2mD0YcEz05LAfs-_v3307-1idf_7w6ey0_K0amavaI3TN4FG2A2poVdM4UNB6atEY8EL25FXXaiN7MNA3ToPwPTnCsgypY_by7t1S_6-NUrZTSI7GEWdatmQb0da1lqbA5__Bi2WLpZ1kpZJKtV23R88OaOsn8naNYcJ4Y__Mr4AXB4DJ4TjEMp-Q_jkNurSgi3t756j0fhko2uTKpBz5EMll65dgQdh9svY2WbuPzQqwt8lao34DyfuV1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232338995</pqid></control><display><type>article</type><title>Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hiatt, William R ; Regensteiner, Judith G ; Creager, Mark A ; Hirsch, Alan T ; Cooke, John P ; Olin, Jeffrey W ; Gorbunov, Georgij N ; Isner, Jeffrey ; Lukjanov, Yurij V ; Tsitsiashvili, Mihail Sh ; Zabelskaya, Tatyana F ; Amato, Antonino</creator><creatorcontrib>Hiatt, William R ; Regensteiner, Judith G ; Creager, Mark A ; Hirsch, Alan T ; Cooke, John P ; Olin, Jeffrey W ; Gorbunov, Georgij N ; Isner, Jeffrey ; Lukjanov, Yurij V ; Tsitsiashvili, Mihail Sh ; Zabelskaya, Tatyana F ; Amato, Antonino</creatorcontrib><description>PURPOSE: We tested the hypothesis that propionyl-L-carnitine would improve peak walking time in patients with claudication. Secondary aims of the study were to evaluate the effects of propionyl-L-carnitine on claudication onset time, functional status, and safety.
SUBJECTS AND METHODS: In this double-blind, randomized, placebo-controlled trial, 155 patients with disabling claudication from the United States (n = 72) or Russia (n = 83) received either placebo or propionyl-L-carnitine (2g/day orally) for 6 months. Subjects were evaluated at baseline and 3 and 6 months after randomization with a graded treadmill protocol at a constant speed of 2 miles per hour, beginning at 0% grade, with increments in the grade of 2% every 2 minutes until maximal symptoms of claudication forced cessation of exercise. Questionnaires were used to determine changes in functional status.
RESULTS: At baseline, peak walking time was 331 ± 171 seconds in the placebo group and 331 ± 187 seconds in the propionyl-L-carnitine group. After 6 months of treatment, subjects randomly assigned to propionyl-L-carnitine increased their peak walking time by 162 ± 222 seconds (a 54% increase) as compared with an improvement of 75 ± 191 seconds (a 25% increase) for those on placebo (
P <0.001). Similar improvements were observed for claudication onset time. Propionyl-L-carnitine treatment significantly improved walking distance and walking speed (by the Walking Impairment Questionnaire), and enhanced physical role functioning, reduced bodily pain, and resulted in a better health transition score (by the Medical Outcome Study SF-36 Questionnaire). The incidence of adverse events and study discontinuations were similar in the two treatment groups.
CONCLUSIONS: Propionyl-L-carnitine safely improved treadmill exercise performance and enhanced functional status in patients with claudication.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/S0002-9343(01)00704-5</identifier><identifier>PMID: 11382369</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Biological and medical sciences ; Cardiovascular system ; Carnitine - analogs & derivatives ; Carnitine - pharmacology ; Clinical trials ; Double-Blind Method ; Exercise ; Exercise Tolerance - drug effects ; Female ; Humans ; Hypotheses ; Intermittent Claudication - physiopathology ; Male ; Medical research ; Medical sciences ; Middle Aged ; Miscellaneous ; Pharmacology. Drug treatments</subject><ispartof>The American journal of medicine, 2001-06, Vol.110 (8), p.616-622</ispartof><rights>2001 Excerpta Medica Inc.</rights><rights>2002 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Jun 1, 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-6da197fda28fa418377c1318de8a551d02bed398452b151b7c410dbeceaeae5e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002934301007045$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14143774$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11382369$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hiatt, William R</creatorcontrib><creatorcontrib>Regensteiner, Judith G</creatorcontrib><creatorcontrib>Creager, Mark A</creatorcontrib><creatorcontrib>Hirsch, Alan T</creatorcontrib><creatorcontrib>Cooke, John P</creatorcontrib><creatorcontrib>Olin, Jeffrey W</creatorcontrib><creatorcontrib>Gorbunov, Georgij N</creatorcontrib><creatorcontrib>Isner, Jeffrey</creatorcontrib><creatorcontrib>Lukjanov, Yurij V</creatorcontrib><creatorcontrib>Tsitsiashvili, Mihail Sh</creatorcontrib><creatorcontrib>Zabelskaya, Tatyana F</creatorcontrib><creatorcontrib>Amato, Antonino</creatorcontrib><title>Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>PURPOSE: We tested the hypothesis that propionyl-L-carnitine would improve peak walking time in patients with claudication. Secondary aims of the study were to evaluate the effects of propionyl-L-carnitine on claudication onset time, functional status, and safety.
SUBJECTS AND METHODS: In this double-blind, randomized, placebo-controlled trial, 155 patients with disabling claudication from the United States (n = 72) or Russia (n = 83) received either placebo or propionyl-L-carnitine (2g/day orally) for 6 months. Subjects were evaluated at baseline and 3 and 6 months after randomization with a graded treadmill protocol at a constant speed of 2 miles per hour, beginning at 0% grade, with increments in the grade of 2% every 2 minutes until maximal symptoms of claudication forced cessation of exercise. Questionnaires were used to determine changes in functional status.
RESULTS: At baseline, peak walking time was 331 ± 171 seconds in the placebo group and 331 ± 187 seconds in the propionyl-L-carnitine group. After 6 months of treatment, subjects randomly assigned to propionyl-L-carnitine increased their peak walking time by 162 ± 222 seconds (a 54% increase) as compared with an improvement of 75 ± 191 seconds (a 25% increase) for those on placebo (
P <0.001). Similar improvements were observed for claudication onset time. Propionyl-L-carnitine treatment significantly improved walking distance and walking speed (by the Walking Impairment Questionnaire), and enhanced physical role functioning, reduced bodily pain, and resulted in a better health transition score (by the Medical Outcome Study SF-36 Questionnaire). The incidence of adverse events and study discontinuations were similar in the two treatment groups.
CONCLUSIONS: Propionyl-L-carnitine safely improved treadmill exercise performance and enhanced functional status in patients with claudication.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Carnitine - analogs & derivatives</subject><subject>Carnitine - pharmacology</subject><subject>Clinical trials</subject><subject>Double-Blind Method</subject><subject>Exercise</subject><subject>Exercise Tolerance - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Intermittent Claudication - physiopathology</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Pharmacology. Drug treatments</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0VtrFTEQB_Agij1WP4ISBMU-rGZy2cuTlOINCgrqc5hNZjVlbybZXr69Oe1RQfIQAr8kM_Nn7CmI1yCgfvNVCCGrTmn1SsCJEI3QlbnHdmCMqRqo5X22-0uO2KOULspRdKZ-yI4AVCtV3e3Yjy9xWcMy34zVeeUwziGHmXiY1rhcUuJ0TdGFRHylOCxxwtkRx9nzYZtdLhdx5Clj3hIPM18xB5pz4lch_-RuxM0Hh3v2mD0YcEz05LAfs-_v3307-1idf_7w6ey0_K0amavaI3TN4FG2A2poVdM4UNB6atEY8EL25FXXaiN7MNA3ToPwPTnCsgypY_by7t1S_6-NUrZTSI7GEWdatmQb0da1lqbA5__Bi2WLpZ1kpZJKtV23R88OaOsn8naNYcJ4Y__Mr4AXB4DJ4TjEMp-Q_jkNurSgi3t756j0fhko2uTKpBz5EMll65dgQdh9svY2WbuPzQqwt8lao34DyfuV1g</recordid><startdate>20010601</startdate><enddate>20010601</enddate><creator>Hiatt, William R</creator><creator>Regensteiner, Judith G</creator><creator>Creager, Mark A</creator><creator>Hirsch, Alan T</creator><creator>Cooke, John P</creator><creator>Olin, Jeffrey W</creator><creator>Gorbunov, Georgij N</creator><creator>Isner, Jeffrey</creator><creator>Lukjanov, Yurij V</creator><creator>Tsitsiashvili, Mihail Sh</creator><creator>Zabelskaya, Tatyana F</creator><creator>Amato, Antonino</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Sequoia S.A</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20010601</creationdate><title>Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication</title><author>Hiatt, William R ; Regensteiner, Judith G ; Creager, Mark A ; Hirsch, Alan T ; Cooke, John P ; Olin, Jeffrey W ; Gorbunov, Georgij N ; Isner, Jeffrey ; Lukjanov, Yurij V ; Tsitsiashvili, Mihail Sh ; Zabelskaya, Tatyana F ; Amato, Antonino</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-6da197fda28fa418377c1318de8a551d02bed398452b151b7c410dbeceaeae5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Carnitine - analogs & derivatives</topic><topic>Carnitine - pharmacology</topic><topic>Clinical trials</topic><topic>Double-Blind Method</topic><topic>Exercise</topic><topic>Exercise Tolerance - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Intermittent Claudication - physiopathology</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hiatt, William R</creatorcontrib><creatorcontrib>Regensteiner, Judith G</creatorcontrib><creatorcontrib>Creager, Mark A</creatorcontrib><creatorcontrib>Hirsch, Alan T</creatorcontrib><creatorcontrib>Cooke, John P</creatorcontrib><creatorcontrib>Olin, Jeffrey W</creatorcontrib><creatorcontrib>Gorbunov, Georgij N</creatorcontrib><creatorcontrib>Isner, Jeffrey</creatorcontrib><creatorcontrib>Lukjanov, Yurij V</creatorcontrib><creatorcontrib>Tsitsiashvili, Mihail Sh</creatorcontrib><creatorcontrib>Zabelskaya, Tatyana F</creatorcontrib><creatorcontrib>Amato, Antonino</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hiatt, William R</au><au>Regensteiner, Judith G</au><au>Creager, Mark A</au><au>Hirsch, Alan T</au><au>Cooke, John P</au><au>Olin, Jeffrey W</au><au>Gorbunov, Georgij N</au><au>Isner, Jeffrey</au><au>Lukjanov, Yurij V</au><au>Tsitsiashvili, Mihail Sh</au><au>Zabelskaya, Tatyana F</au><au>Amato, Antonino</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>2001-06-01</date><risdate>2001</risdate><volume>110</volume><issue>8</issue><spage>616</spage><epage>622</epage><pages>616-622</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>PURPOSE: We tested the hypothesis that propionyl-L-carnitine would improve peak walking time in patients with claudication. Secondary aims of the study were to evaluate the effects of propionyl-L-carnitine on claudication onset time, functional status, and safety.
SUBJECTS AND METHODS: In this double-blind, randomized, placebo-controlled trial, 155 patients with disabling claudication from the United States (n = 72) or Russia (n = 83) received either placebo or propionyl-L-carnitine (2g/day orally) for 6 months. Subjects were evaluated at baseline and 3 and 6 months after randomization with a graded treadmill protocol at a constant speed of 2 miles per hour, beginning at 0% grade, with increments in the grade of 2% every 2 minutes until maximal symptoms of claudication forced cessation of exercise. Questionnaires were used to determine changes in functional status.
RESULTS: At baseline, peak walking time was 331 ± 171 seconds in the placebo group and 331 ± 187 seconds in the propionyl-L-carnitine group. After 6 months of treatment, subjects randomly assigned to propionyl-L-carnitine increased their peak walking time by 162 ± 222 seconds (a 54% increase) as compared with an improvement of 75 ± 191 seconds (a 25% increase) for those on placebo (
P <0.001). Similar improvements were observed for claudication onset time. Propionyl-L-carnitine treatment significantly improved walking distance and walking speed (by the Walking Impairment Questionnaire), and enhanced physical role functioning, reduced bodily pain, and resulted in a better health transition score (by the Medical Outcome Study SF-36 Questionnaire). The incidence of adverse events and study discontinuations were similar in the two treatment groups.
CONCLUSIONS: Propionyl-L-carnitine safely improved treadmill exercise performance and enhanced functional status in patients with claudication.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11382369</pmid><doi>10.1016/S0002-9343(01)00704-5</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American journal of medicine, 2001-06, Vol.110 (8), p.616-622 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70866425 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Anti-Inflammatory Agents, Non-Steroidal - pharmacology Biological and medical sciences Cardiovascular system Carnitine - analogs & derivatives Carnitine - pharmacology Clinical trials Double-Blind Method Exercise Exercise Tolerance - drug effects Female Humans Hypotheses Intermittent Claudication - physiopathology Male Medical research Medical sciences Middle Aged Miscellaneous Pharmacology. Drug treatments |
| title | Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A03%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Propionyl-L-carnitine%20improves%20exercise%20performance%20and%20functional%20status%20in%20patients%20with%20claudication&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=Hiatt,%20William%20R&rft.date=2001-06-01&rft.volume=110&rft.issue=8&rft.spage=616&rft.epage=622&rft.pages=616-622&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/S0002-9343(01)00704-5&rft_dat=%3Cproquest_pubme%3E70866425%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232338995&rft_id=info:pmid/11382369&rft_els_id=S0002934301007045&rfr_iscdi=true |